Login to Your Account



Stomping on an Oncogenic Pathway

Genentech's Love Affair with HER2 Leads to Three Targeted Drugs

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, June 18, 2012

Nearly 14 years after the approval of Herceptin (trastuzumab), Genentech Inc. has a second approved drug targeting HER2, Perjeta (pertuzumab).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription